Innoviva (INVA) Total Current Liabilities (2010 - 2026)
Innoviva's (INVA) quarterly Total Current Liabilities came in at $36.6 million in Q1 2026, down 84.43% YoY from $234.7 million in Q1 2025, and down 26.44% on a QoQ basis from $49.7 million in Q4 2025.
Innoviva (INVA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Total Current Liabilities data on file, last reported at $36.6 million in Q1 2026.
- Quarterly Total Current Liabilities fell 84.43% year-over-year to $36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.6 million (down 84.43% YoY) and the FY2025 annual result came in at $49.7 million, down 78.95% from the prior year.
- Total Current Liabilities retreated to $36.6 million in Q1 2026, from $49.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $246.6 million in Q2 2025 to a low of $7.0 million in Q3 2022.
- A 5-year average of $96.1 million and a median of $49.7 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 2771.37% — and 2026, when it plunged 84.43%.
- Tracing INVA's Total Current Liabilities over 5 years: stood at $135.0 million in 2022, then sank by 71.75% to $38.1 million in 2023, then soared by 519.09% to $236.1 million in 2024, then plunged by 78.95% to $49.7 million in 2025, then decreased by 26.44% to $36.6 million in 2026.
- The last three Total Current Liabilities figures came in at $36.6 million (Q1 2026), $49.7 million (Q4 2025), and $140.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 47.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.06 Mn |
| Mar 31, 2026 | 36.56 Mn |
| Dec 31, 2025 | 49.70 Mn |
| Sep 30, 2025 | 139.95 Mn |
| Jun 30, 2025 | 246.56 Mn |
| Mar 31, 2025 | 234.75 Mn |
| Dec 31, 2024 | 236.08 Mn |
| Sep 30, 2024 | 118.20 Mn |
| Jun 30, 2024 | 28.21 Mn |
| Mar 31, 2024 | 29.88 Mn |
| Dec 31, 2023 | 38.13 Mn |
| Sep 30, 2023 | 21.88 Mn |
| Jun 30, 2023 | 39.40 Mn |
| Mar 31, 2023 | 38.14 Mn |
| Dec 31, 2022 | 134.97 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Jun 30, 2022 | 125.91 Mn |
| Mar 31, 2022 | 109.23 Mn |
| Dec 31, 2021 | 5.81 Mn |
| Sep 30, 2021 | 5.25 Mn |